Brief Article
Copyright ©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Dec 28, 2013; 19(48): 9328-9333
Published online Dec 28, 2013. doi: 10.3748/wjg.v19.i48.9328
Table 3 Univariate analysis predicting the following
OR (95%CI)P value
HCC in patients with CHC
HBcAb(+)1.90 (1.28-3.04)0.02
HBsAb(-) and HBcAb(+)3.24 (2.28-4.62)< 0.01
HCC in cirrhotic patients with CHC
HBcAb(+)1.54 (1.18-2.54)0.02
HBsAb(-) and HBcAb(+)2.14 (1.68-3.82)0.01
HCC in patients with CHC when controlled for covariates1
HBcAb(+)1.84 (1.22-3.08)0.01
HBsAb(-) and HBcAb(+)2.98 (2.12-5.08)< 0.01
HCC in cirrhotic patients with CHC when controlled for covariates1
HBcAb(+)1.66 (1.22-3.24)0.01
HBsAb(-) and HBcAb(+)2.10 (1.72-4.04)< 0.01
HCC in cirrhotic African American patients with CHC when controlled for covariates1
HBcAb(+)2.08 (1.42-3.6)< 0.01
HBsAb(-) and HBcAb(+)2.58 (1.82-4.44)< 0.01
1Body mass index, albumin, prothrombin time, human immunodeficiency virus co-infection and alcohol consumption. HCC: Hepatocellular carcinoma; CHC: Chronic hepatitis C; HBcAb: Hepatitis B surface antibody; HBcAb: Hepatitis B core antibody.